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Optimal amplification conditions for D16S3399 
polymorphic STS axin-1 gene marker
Abstract
We investigated D16S3399 marker and affirmed it as a highly polymor-
phic marker useful for the analysis of the human axin-1 gene. Axin-1 acts 
as a tumor suppressor gene and its protein is an inhibitor of the Wnt signal-
ing pathway. We report on heterozygosity status, alleles frequency observed 
in a preliminary group of Croatian subjects and the optimal amplification 
conditions for D16S3399 marker. The amplified CA repeat was confirmed 
by direct sequencing.
fINdINGS
In this report we would like to present data on the optimal amplification conditions and observed percentage of heterozygosity of the D16S3399 
(also known as 16PTEL03, TEL-16p03 and Tel-16p03) polymorphic 
STS marker for the axin-1 gene. The literature and gene databases lack 
this data without any specific characterization and required experimental 
conditions. The marker is reported as STS (sequence tagged site) and 
found by e-PCR (1) in Homo sapiens sequences. We investigated D16S3399 
marker and affirmed it as a highly polymorphic marker very useful for 
microsatellite instability (MSI) and loss of heterozygosity (LOH) analysis 
of the axin-1 gene. Axin-1 (aliases: AxIN, hAxIN, MGC52315, Axis 
inhibitor 1, NCBI Locus ID 8312) acts as a tumor suppressor gene and 
its protein is an inhibitor of the Wnt signaling pathway (2-4). As a scaffold 
protein, its main role is binding multiple members of Wnt signaling and 
formation of the b-catenin dest ruction complex (5). Axin-1 gene is lo-
cated on the short arm of the chromosome 16 at position 16p13.3, extend-
ing from 337 440 to 402 676. Axin-1 has two predominat isoforms, 
isoform a consists of 11 exons and has full gene transcript product length 
of 3675 bp. Isoform b lacks an in-frame exon in the 3’ coding region and 
is shorter with sequence length of 3567 bp (6). 
D16S3399 polymorphism is 183 bp long dinucleotide CA repeat that 
extends from 145 245 bp telomeric region to position 145 427 bp of the 
chro mosome 16p. The primers used were found on National Center for 
Bio technology Information site, UniSTS Integrating Markers and Maps 
http://www.ncbi.nlm.nih.gov/genome/sts/sts.cgi?uid=9302&MAx-
HITS=6
Experimental Procedures
The D16S3399 polymorphic region linked to the axin-1 gene was 
amplified in a volume of 25 ml. Different conditions were tested includ-
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Figure 1. Sequence for the D16S3399 polymorphic STS marker. 183 bp fragment was sequenced with appropriate primers, and analyzed on 
ABI PRISM 310. 
Figure 2. Alleles of the D16S3399 visualized on Spreadex EL 400 
Mini gels (Elchrom Scientific, Switzerland) stained with Syber-
Gold (Molecular Probes, Netherlands). Lane M- molecular DNA 
standard; lanes 1, 2, 3, 4 heterozygous samples from blood and 
human tissue.
consisting of 30 seconds of denaturation at 96°C, 30 sec-
onds of annealing at 56°C and 30 seconds of extension at 
72°C adding 1 extra second after every cycle. A final ex-
tension at 72°C was lengthened to 10 minutes. PCR prod-
ucts were analyzed on 2% agarose gels.
In order to verify that our PCR products are compat-
ible with the reported sequence on the web we sequenced 
our 183 bp product. We confirmed D16S3399 by direct 
sequencing.
PCR products were separated by agarose gel electro-
phoresis and visualized by ethidium bromide staining. 
DNA fragments were cut out and isolated from agarose 
gel (qIAquick gel extraction Kit; qIAGEN, Hilden, Ger-
many). Sequencing reactions were performed with appro-
priate primers in a BigDye Terminator v1.1; Applied Bio-
systems, Foster City, USA, and analyzed on ABI PRISM 
310. All sequences were confirmed by bidirectional se-
quencing of PCR products generated by at least two in-
dependent reactions (Figure 1). 
Allelic heterozygosity of the D16S3399 was visualized 
on Spreadex EL 400 Mini gels (Elchrom Scientific, Swit-
zerland) stained with SyberGold (Molecular Probes, 
Netherlands). The percent of heterozygous samples was 
83%. (Figure 2).
Our results of the experimental PCR were compatible 
to the e-PCR of this STS. The reported optimal condi-
tions for D16S3399 polymorphic STS marker would be 
useful for further analysis of the axin-1 gene. Specific ge-
ing MgCl2 concentrations, template DNA concentra-
tions, primer and dNTP concentrations and Taq units. 
The optimal conditions were as follows: 5 pmol of each 
primer (5’- GGGCCATTATTCAGCCAATC -3’ and 
5’-ACCTAGATCCCTCCAGGTTT -3’), 200-400 ng 
DNA, 2.5 µl PCR buffer (500 mM KCl, 100 mM Tris-
HCl, pH 8.3), 2 mM MgCl2, 2.5 mM of each dNTP, 5 
U/µl Taq polymerase (Promega, USA). 
Optimal polymerase chain reaction (PCR) conditions 
for D16S3399 marker were as follows. Reaction was pre-
ceded by 3-minute initial denaturation at 95°C. Samples 
were subjected to 35 cycles of three-step amplification 
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netic variations represent important tools for human ge-
netics (7, 8) and contribute to the many analyses of dis-
eases including chromosomal abnormalities in tumors.
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